Mohamed Adel Fakhro
Mohamed Adel Fakhro Chairman, Infinite Loop | Entrepreneur | Technology & Innovation Advocate
Some business legacies are built to preserve what already works. Others reach a point where preservation is no longer enough.
In this episode of The Matrix Green Pill Podcast, Hilmarie Hutchison speaks with Mohamed Adel Fakhro, Chairman of Infinite Loop, entrepreneur, investor, and technology advocate, about what it means to carry a long commercial inheritance into fields where the answers are still being discovered.
Mohamed comes from one of Bahrain’s established merchant families, with a business legacy that stretches back more than 138 years. That history matters. It gives him a deep respect for cash flow, commercial discipline, and the practical realities of building companies.
His current work now sits far from traditional trade, spanning biotechnology, artificial intelligence, genomics, robotics, generic medicines, cultured meat, and the broader question of sovereign research and development.
The episode is not only about new technology. It is about what happens when a region, a business, and a leader begin to imagine themselves differently.
The Green Pill Moment
→ Listen to the full podcast conversation
Mohamed’s Green Pill moment came through reading Elon Musk’s biography around 2016 or 2017. Until then, his path had followed a more familiar route: Stanford, Bahrain, the family business, and traditional ventures. The biography changed the frame. It showed him that a business did not have to be only a restaurant, a property development company, a trading company, or a hotel. It could be built around a problem big enough to matter beyond the balance sheet.
The biography widened his view of what business could attempt, from addressing disease and climate change to building technologies that seemed outlandish until someone made them real.
That idea did not lead Mohamed into imitation. It led him to another question: what kinds of companies could be built in the Gulf if the ambition was not only to consume the future but also to create part of it?
From Trade to Research
Mohamed is clear that the shift from traditional business to research-led innovation is not romantic. In a trading business, profitability can begin quickly because a product is bought and sold, and the margin is visible. In biotechnology or AI, the economics are different because research, regulation, talent, and product development all take time.
That creates a real tension for leaders from commercially disciplined environments. Cash flow still matters. Mohamed does not pretend otherwise. In fact, he argues that every business survives or dies by it. But the kind of patience required for research is different from the patience required for trade. Innovation cannot be managed only by the rhythm of short-term returns.
This is where Mohamed’s thinking becomes interesting. He is not rejecting the merchant instinct so much as stretching it. His approach to medicine, for example, includes generic drugs because they can expand access, support cash flow, and serve as a bridge to deeper research over time. That is not a retreat from ambition but a way to keep ambition alive long enough to be useful.
The Sovereignty Question
One of the strongest threads in the conversation is Mohamed’s belief that the Middle East must move from being a consumer of technology to a creator of intellectual property.
He uses cultured meat as one example. For an arid region that has historically depended on trade routes and external supply for many essentials, food security is part of long-term resilience. Mohamed sees technologies such as cultured meat as one possible route toward greater regional self-sufficiency.
That same logic applies to healthcare, biotechnology, AI, and advanced research. A region that only imports solutions remains dependent on other people’s priorities, pricing, supply chains, and political stability. A region that builds research capability begins to shape its own future.
The point is not national pride for its own sake. It is operational independence.
The Monday Move
For all the scale of Mohamed’s ideas, his Monday Move is deliberately basic: coffee, email, the office, and a daily to-do list. There is something revealing in that simplicity. The imaginative work may happen at night or on weekends, away from daily pressure, but the week itself still needs grounding.
For a leader working across fields where the timelines can stretch for years, that daily discipline matters. Long-term imagination still has to survive the ordinary demands of Monday morning.
The Green Pill Reflection
The final reflection brings the episode back to the tension Mohamed carries from his own business heritage.
Asked which merchant habit could hurt the innovation mission he is trying to build, he points to short-term thinking. The instinct to judge a business too quickly by early financial performance can be useful in some environments, but damaging in others.
Research-led companies need a different tolerance for uncertainty. That does not mean ignoring financial reality. It means knowing which kind of business you are building before deciding how quickly it should prove itself.
The Question to Sit With
Where are you applying old measures of success to a future that requires a different kind of patience?
Listen for the Full Context
→ Listen to the full podcast conversation
This executive perspective captures the central thread of the conversation. The episode itself explores Mohamed Adel Fakhro’s journey from Stanford and family business into biotechnology, AI, generic medicines, cultured meat, sovereign R&D, and the future of innovation in the Middle East.
For leaders, the takeaway is clear: imagination is not escapism when it is disciplined enough to become infrastructure. It is how a legacy begins to build what comes next.
